Você procurou por: preparation of monitoring capacity develo... (Holandês - Espanhol)

12 september 1998 - progress in the technical preparation of the euro banknotes
12 september 1998 - progress in the technical preparation of the euro banknotes

engels for production of food preparations of cn code 190110
en inglés for production of food preparations of cn code 190110

- for production of food preparations of cn code 1901 10
- for production of food preparations of cn code 1901 10

de uitgaven betreffende personeelskosten voor de uitvoering van laboratoriumtests, bemonstering of monitoring, en betreffende verbruiksgoederen en algemene kosten ten behoeve van de surveillancestudies moeten subsidiabel zijn overeenkomstig de regels in bijlage iii.
los gastos relativos a costes de personal para la ejecución de los análisis de laboratorio, toma de muestras, seguimiento, bienes fungibles y de los gastos generales dedicados a los estudios de vigilancia serán subvencionables con arreglo a las normas establecidas en el anexo iii.

- suspension for injection - monodose preparation of 1 ml contains hepatitis b surface antigen s, pre-s1 and pre s2 20 µg - 2 presentations
suspension for - injection - monodose preparation - of 1 ml contains - hepatitis b surface antigen s, pre-s1 and pre s2 20 µg

- broken rice of cn code 1006 40 00 for production of food preparations of cn code 1901 10
- broken rice of cn code 1006 40 00 for production of food preparations of cn code 1901 10

concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia

suspension for injection a monodose preparation of 0.5 ml contains streptococcus pneumoniae: saccharide suspension of serotype 4 2 µg serotype 9v 2 µg serotype 14 2 µg serotype 18c 2 µg serotype 19f 2 µg serotype 23f 2 µg serotype 6b 4 µg conjugated to crm197 carrier protein ∼ 20 µg
- b

ex ante evaluations (impact assessments) in preparation of all new proposals _bar_ european commission _bar_ ongoing _bar_
ex ante evaluations (impact assessments) in preparation of all new proposals _bar_ european commission _bar_ ongoing _bar_

adjustment for multiplicity and related topics points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: adjustment for baseline covariates points to consider on clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: